Denali-Sanofi's ALS drug fails to meet mid-stage trial goal

Denali-Sanofi's ALS drug fails to meet mid-stage trial goal

Source: 
Reuters
snippet: 

 Drug developer Denali Therapeutics (DNLI.O) said on Friday its and partner Sanofi's (SASY.PA) experimental drug for a fatal neurodegenerative disease failed to slow decline of motor function in a mid-stage study.